On April 21, Guangzhou Huangpu District and Guangzhou High-tech Zone held the fourth "Half Moon Talk" press conference in 2021, focusing on the high-quality development of the biomedical industry, a key pillar industry in the district.
The reporter learned from the meeting that in 2020, the R&D investment of Huangpu District and Guangzhou High-tech Zone accounted for 4.38% of GDP, becoming the first area in Guangzhou where the intensity of R&D investment exceeded 4%.
Biomedicine is the key development industry of the "Huangpu Manufacturing Trillion Plan" in the district during the "14th Five-Year Plan". At present, there are more than 3,000 biomedical enterprises gathered in the region, and the revenue scale exceeded 100 billion yuan, and it was awarded the Best Biomedical Park Award in China and the Top Ten Parks in the Innovative Drug Potential Index of China Biomedical Park, becoming the first echelon of the development of the domestic biomedical industry.
In 2020, the operating income of biomedical enterprises in the region was 148.591 billion yuan, an increase of 14.8% year-on-year; in the first quarter of 2021, the operating income was 39.614 billion yuan, an increase of 25.5% year-on-year.
It is worth mentioning that Zhong Nanshan and Zhang Boli have led related projects here.
Zhong Nanshan, an academician of the Chinese Academy of Engineering, serves as the chief scientist to build a large scientific research facility for human cell lineage, which will build a world-class scientific center for cell science research and life health leadership around the national life and health development strategy. The Guangdong New Huangpu Institute of Traditional Chinese Medicine, led by Zhang Boli, an academician of the Chinese Academy of Engineering, is committed to building a highland for innovation in traditional Chinese medicine technology in the Greater Bay Area.
Relying on "two cities and one island"
Forward-looking layout of national strategic scientific and technological forces
In recent years, Huangpu District and Guangzhou High-tech Zone have expanded the space for industrial development by focusing on the national platform, and have formed a "two cities and one island" biomedical industry development pattern.
Guangzhou Science City gives full play to the advantages of the core park of the national high-tech zone, focusing on pilot and incubation, and building the world's top biomedical science and technology achievement transformation center; the Sino-Singapore Guangzhou Knowledge City gives full play to the advantages of the national bilateral cooperation project, builds a biomedical value innovation park with high standards, gathers well-known biomedical projects at home and abroad such as GE, Lonza, BeiGene, etc., and builds a world-class biomedical leading enterprise agglomeration area and an international first-class life science research and development collaboration demonstration area; Guangzhou International Biological Island layout Guangzhou laboratory, High-end R&D platforms such as Bio-Island Laboratory gather more than 510 biomedical enterprises such as Jinyu Medical, benchmark Boston in the United States and Cambridge in the United Kingdom, and create a national biomedical policy innovation pilot zone and the world's top biomedical and biosafety research and development center.
Facing the major needs of the country, Huangpu District and Guangzhou High-tech Zone rely on the "two cities and one island" industrial platform to forward-looking layout of national strategic scientific and technological forces.
Located on the biological island, the Guangzhou laboratory, with Zhong Nanshan, the recipient of the "Order of the Republic", serves as the director of the laboratory, focusing on the prevention and control of respiratory infectious diseases and the sudden public health incidents caused by them, and will become a large-scale comprehensive research base and original innovation source with global influence.
Bio Island Laboratory is one of the first batch of laboratories in Guangdong Province, gathering 12 academicians of the two academies such as Xu Tao and Song Erwei, introducing 107 PI (chief researchers and academic leaders), and is a base for cutting-edge research, clinical application, achievement transformation and high-level talents in regenerative medicine and health, and has made outstanding contributions to the construction of the new crown epidemic prevention and control system in our province.
In addition, Zhong Nanshan, an academician of the Chinese Academy of Engineering, as the chief scientist, built a large scientific research facility for human cell lineage, and built a world-class scientific center for cell science research and life and health leadership around the national life and health development strategy. Academician He Fuchu led the construction of the Huiyan Large Facilities Project, which provides intelligent solutions for smart medical treatment, protein drug research and development, and biosecurity.
The Guangdong New Huangpu Institute of Traditional Chinese Medicine, led by Zhang Boli, an academician of the Chinese Academy of Engineering, is committed to building a highland for innovation in traditional Chinese medicine technology in the Greater Bay Area.
It is reported that Huangpu District and Guangzhou High-tech Zone have been identified as a total of 8 provincial high-level innovation research institutes, accounting for 2/3 of the province.
The biomedical industry bucked the trend
Accelerate the acquisition of the commanding heights of global innovation
Huangpu District and Guangzhou High-tech Zone closely follow the direction of "developing high technology and realizing industrialization" and improve the ability of science and technology to serve the quality of the economy. Facing the main battlefield of the economy, the biomedical industry has risen against the trend.
According to statistics, in 2020, the operating income of pharmaceutical manufacturing and medical device enterprises above designated size in the whole district increased by 37% year-on-year; there were 4 newly listed biomedical enterprises, with a total of 14, accounting for 73% of the city. The 27 top biomedical key projects are progressing smoothly, with a total investment of 86.4 billion yuan. After the completion of beigene Guangzhou, the production capacity of the BeiGene Guangzhou base will reach up to 200,000 liters, which will become one of the self-owned biopharmaceutical production bases of local innovative pharmaceutical companies with the largest production capacity in China and even Asia.
Under the epidemic situation, the district has accelerated scientific and technological innovation for people's life and health, comprehensively built a new crown pneumonia epidemic prevention and control system integrating "prevention, detection and treatment", and achieved three "national firsts" and three "national largest": the first batch of nucleic acid diagnostic kits, the first batch of antibody rapid detection kits, and the first batch of nucleic acid rapid detection kits were born in the district; the region has the country's largest nucleic acid test kit production enterprise Daan Gene, the country's largest antibody testing kit manufacturer Wanfu Biologics, and Golden Mile Medicine, the institution with the highest number of tests in the world.
Focusing on safety and controllability, and fighting the key core technology battle, the biomedical industry in Huangpu District and Guangzhou High-tech Zone is accelerating to seize the global commanding heights.
In 2019, BIOTEC developed the first adalimumab biosimilar drug that was listed in China, forcing the original research drug Xiu Meile, known as the "king of medicine", to significantly reduce the price, a drop of 83%. In March this year, the State Drug Administration approved the new specification of adalimumab injection 20mg/0.4ml (pre-filled, subcutaneous injection) independently developed by BIOTECH Biologics, which is the first domestic low-dose subcutaneous injection dosage form of adalimumab, gradually getting rid of the situation of excessive dependence on foreign innovative drugs.
Mingkang Biology's "Ming Fu Le" fills the domestic gap, Nuocheng Jianhua has developed the world's third BTK inhibitor, Qiji Pharmaceutical's "Jinrong Granules" has obtained the first new drug certificate in the region in recent years, Kangli Ming Bio has been approved as China's first intestinal cancer fecal gene test kit, and Lithophyllite Medicine has been approved as the domestic "first certificate of tumor NGS"... In Huangpu District and Guangzhou High-tech Zone, the biomedical industry has burst out of strong development vitality, more than 200 enterprises have participated in the fight against the epidemic, and more than 3,000 enterprises have bravely innovated, practicing "small and medium-sized enterprises can do great things" with practical actions.
Guaranteed by systems and policies
Multi-level to build a biomedical talent echelon
In recent years, in order to promote the development of the biomedical industry, Huangpu District and Guangzhou High-tech Zone have focused on creating a policy "soft environment" for industrial development, and maintaining the continuity of policies, improving the mechanism of introducing, cultivating and serving high-end talents, providing talent support for scientific and technological innovation, and creating a multi-level and multi-angle biomedical talent echelon.
Since 2017, the district has taken the lead in launching the "IAB Development Implementation Opinions" in the country, of which the "B" policy is a special policy tailored for the biomedical industry; in 2020, in order to attract major biomedical projects to land in Huangpu, the "8 high-end biopharmaceuticals" were launched; in March this year, the "10 Biomedicals" were introduced to promote the high-quality development of the biopharmaceutical industry.
It is worth mentioning that in the "8 articles of high-end biopharmaceuticals", a single project can give a maximum of 500 million yuan in fixed asset investment to complete the agreed fixed asset investment, which is the single measure with the largest support for the national biomedical industry. "Biomedical 10" proposed that in the process of the advent of a new drug research and development, the policy of superimposed city, enterprises can get up to about 100 million yuan of research and development incentives, and the support is the first in the country.
Biomedical industry support policies have played an obvious role in driving the development of the industry. Take the reward clause in the "IAB Development Implementation Opinions" for the R&D innovation of biomedical enterprises and the industrialization of innovative achievements as an example.
By the end of 2020, a total of 121 approvals have been awarded to 33 units in the district, and 1 approval has been industrialized, 2 approvals have been submitted for listing and registration, 9 projects have entered Phase 3 clinical, and 26 approvals have entered Phase 2 clinical, providing financial support for the clinical research and development of enterprises. In terms of new drug certificates, BIOTEC's adalimumab injection received a reward of 10 million yuan, and in 2020, the first year of listing achieved product sales revenue of nearly 200 million yuan.
At the same time, huangpu district and Guangzhou development zone have successively settled down major biomedical industrialization projects led by a group of scientists such as "10 beautiful jades", "8 overseas cutting-edge talents" and innovation and entrepreneurship leading talents, such as BeiGene Shenzhou of Academician Wang Xiaodong's team, Nuocheng Jianhua of Academician Shi Yigong's team, and Guangzhou Saina of Academician Xie Xiaoliang's team, which have produced a huge demonstration effect in the biomedical industry. At present, the district gathers more than 40 academician expert teams such as Zhong Nanshan, Xu Tao, Shi Yigong, etc., and more than 700 high-end life science talents.
[South + reporter] Wu Yulun
【Photography】 Liu Liqin
[Correspondent] Fan Minling Zhong Feixing
【Author】 Wu Yulun; Liu Liqin
【Source】 Southern Press Media Group South + client
Source: South+ - Create more value